Using the same dose that was required to suppress subcutaneous tumor growth and prevent bone loss in a hormone-deprived environment, everolimus was proven to be effective in preventing the establishment and progression of breast cancer bone metastases when mice were intracardially inoculated with the ER-negative, bone-seeking MDA-MB-231 cells (Fig. 5a–c). This evidence concerns the gene ESR1 and neoplasm.